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A B S T R A C T
Background
Invasive aspergillosis (IA) is themost common life-threatening opportunistic invasive mould infection in immunocompromised people.
Early diagnosis of IA and prompt administration of appropriate antifungal treatment are critical to the survival of people with IA.
Antifungal drugs can be given as prophylaxis or empirical therapy, instigated on the basis of a diagnostic strategy (the pre-emptive
approach) or for treating established disease. Consequently there is an urgent need for research into both new diagnostic tools and
drug treatment strategies. Newer methods such as polymerase chain reaction (PCR) to detect fungal nucleic acids are increasingly being
investigated.
Objectives
To provide an overall summary of the diagnostic accuracy of PCR-based tests on blood specimens for the diagnosis of IA in immuno-
compromised people.
Search methods
We searchedMEDLINE (1946 to June 2015) andEMBASE (1980 to June 2015).We also searchedLILACS,DARE,HealthTechnology
Assessment, Web of Science and Scopus to June 2015. We checked the reference lists of all the studies identified by the above methods
and contacted relevant authors and researchers in the field.
Selection criteria
We included studies that: i) compared the results of blood PCR tests with the reference standard published by the EuropeanOrganisation
for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG); ii) reported data on false-positive, true-positive, false-
negative and true-negative results of the diagnostic tests under investigation separately; and iii) evaluated the test(s) prospectively in
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cohorts of people from a relevant clinical population, defined as a group of individuals at high risk for invasive aspergillosis. Case-
control studies were excluded from the analysis.
Data collection and analysis
Authors independently assessed quality and extracted data. For PCR assays, we evaluated the requirement for either one or two
consecutive samples to be positive for diagnostic accuracy. We investigated heterogeneity by subgroup analyses. We plotted estimates
of sensitivity and specificity from each study in receiver operating characteristics (ROC) space and constructed forest plots for visual
examination of variation in test accuracy. We performed meta-analyses using the bivariate model to produce summary estimates of
sensitivity and specificity.
Main results
Eighteen primary studies, corresponding to 19 cohorts and 22 data sets, published between 2000 and 2013 were included in the meta-
analyses, with a median prevalence of IA (proven or probable) of 12.0% (range 2.5 to 30.8 %). The majority of people had received
chemotherapy for a haematological malignancy or had undergone a hematopoietic stem cell transplant. Several PCR techniques were
used among the included studies. The sensitivity and specificity of PCR for the diagnosis of IA varied according to the interpretative
criteria used to define a test as positive. The mean sensitivity and specificity were 80.5% (95% CI; 73.0 to 86.3) and 78.5% (67.8 to
86.4) for a single positive test result, and 58.0% (36.5 to 76.8) and 96.2% (89.6 to 98.6) for two consecutive positive test results.
Authors’ conclusions
PCR shows moderate diagnostic accuracy when used as screening tests for IA in high-risk patient groups. Importantly the sensitivity
of the test confers a high negative predictive value (NPV) such that a negative test allows the diagnosis to be excluded. Consecutive
positives show good specificity in diagnosis of IA and could be used to trigger radiological and other investigations or for pre-emptive
therapy in the absence of specific radiological signs when the clinical suspicion of infection is high. When a single PCR positive test is
used as diagnostic criterion for IA in a population of 100 people with a disease prevalence of 13.0% (overall mean prevalence), three
people with IA would be missed (sensitivity 80.5%, 19.5% false negatives), and 19 people would be unnecessarily treated or referred
for further tests (specificity of 78.5%, 21.5% false positives). If we use the two positive test requirement in a population with the
same disease prevalence, it would mean that six IA people would be missed (sensitivity 58.0%, 42.1% false negatives) and three people
would be unnecessarily treated or referred for further tests (specificity of 96.2%, 3.8% false positives). Galactomannan and PCR have
good NPV for excluding disease but the low prevalence of disease limits the ability to rule in a diagnosis. The biomarkers are detecting
different aspects of disease and the combination of both together is likely to be more useful.
P L A I N L A N G U A G E S U M M A R Y
A new, non-invasive diagnostic blood test - polymerase chain reaction - for people at risk of an invasive mould infection
(aspergillosis)
Review question. We planned to review the evidence about the accuracy of polymerase chain reaction (PCR) tests for diagnosing
invasive aspergillosis (IA) in people with defective immune systems from medical treatment such as chemotherapy or following organ
or bone marrow transplant.
Background: IA is a fungal disease caused by Aspergillus, a widespread mould. Most people breathe in Aspergillus spores every day
without becoming ill, however people with weakened immune systems or lung diseases are at a higher risk of developing health problems
due to Aspergillus. IA causes patient afflictions that are classically defined as invasive, saprophytic or allergic. Some types of IA are mild,
but some of them are very serious. IA is the most common life-threatening, opportunistic, invasive fungal infection in people whose
immune systems are compromised. Without treatment, most people with IA will die as a direct result, so early diagnosis and prompt
administration of appropriate antifungal treatment are both critical factors to the survival of these people. As obtaining lung tissue is
hampered by the risks involved, there is a need for new, non-invasive methods such as PCR to detect fungal nucleic acids in blood.
Study characteristics. Themost recent search for studies was conducted in June 2015. Eighteen clinical studies reporting the evaluation
of PCR tests prospectively in cohorts of people at high risk of IA were selected.
Study funding sources. None of the companies involved in the diagnosis of invasive fungal diseases funded any of the studies included
in the review.
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Quality of the evidence. Most studies were at low risk of bias and low concern regarding applicability. However, differences in the
reference standard may have contributed to differences we found in the distribution of cases as being classified as IA or not.
Key results. Several PCR techniques were used in the studies. Pooling the data from the studies showed that sensitivity and specificity
of PCR for the diagnosis of IA varied (from 58 to 80.5 % and from 78.5 to 95.2 %, respectively) according to the interpretative criteria
used to define a test as positive. When used as a diagnostic criterion for IA in a population of 100 people with a disease prevalence of
13.0% (overall mean prevalence), a single PCR positive test would have missed three people with the disease, and falsely classified 19
people as having the disease who would be treated unnecessarily or referred for further tests. A requirement of two positive tests as a
diagnostic criterion in a population with the same disease prevalence would miss six people with the disease and falsely classify three
people as having the disease. These numbers should, however, be interpreted with caution because of the limitations of the reference
standard in allowing consistent assessment of cases as being IA or not. Overall, PCR shows moderate diagnostic accuracy when used
as a screening test for IA in high-risk patient groups. Importantly the sensitivity of the tests confers, with the low prevalence of the
disease, a high negative predictive value such that a negative test allows the diagnosis to be excluded.
B A C K G R O U N D
Target condition being diagnosed
Invasive aspergillosis (IA) is a disease resulting from opportunistic
fungal infection and mainly affects immunocompromised hosts,
particularly neutropenic patients such as those undergoing cancer
treatment and hematopoietic stem cell transplant (HSCT) and
solid organ transplant recipients (Flückiger 2006; Marr 2002).
The highest incidence (10% to 20%) and mortality rates (60% to
90%) of IA have been reported following allogeneic HSCT and
heart, lung or heart/lung transplantation. The principle reason for
such people developing IA is that the underlying disease and its
treatment with chemotherapy induces bone marrow failure result-
ing in profound leucopenia and impaired cell-mediated immunity.
The leucopenia ismarked by a lack of functioning polymorphonu-
clear leukocytes (granulocytes) referred to as neutropenia which
means that the patient lacks the phagocytic white blood cells that
are needed to fight infections, including aspergillosis. The innate
immunity is also impaired leading to a collapse of the local de-
fences of the oral cavity, gastrointestinal tract and respiratory tract.
Damage to the respiratory tract is poorly understood but prevents
the lung from effectively clearing fungal spores, especially those of
Aspergillus fumigatuswhich are small enough to lodge in the alveo-
lar spaces. The lack of local and systemic immune defences means
that any spores that germinate can infect lung tissue and progress
to a full-blown infection. The disease that follows is characterised
by invasion of the capillaries (angioinvasion) which can lead to
further dissemination to other parts of the lung and indeed other
organs, particularly the brain.
Early diagnosis of IA and prompt administration of appropriate
antifungal treatment have been recognised as crucial to the survival
of people with IA (Marr 2002; Walsh 2008). Antifungal drugs
can be given as prophylaxis, as empirical therapy, instigated on
the basis of a diagnostic strategy or for treating established disease.
Clearly, the earlier that treatment is started the better the out-
come. Consequently there is an urgent need for research into new
diagnostic tools to detect infection before disease becomes man-
ifest, to allow effective treatment strategies to be developed. The
polymerase chain reaction (PCR) is becoming increasingly pop-
ular (Hope 2005; Donnelly 2006; Mengoli 2009; Tuon 2007),
however it was not considered mature enough to be included in
the international consensus definitions of the The European Or-
ganisation for Research and Treatment of Cancer/Mycoses Study
Group (EORTC/MSG); (Ascioglou 2002; De Pauw 2008). The
prevalence of IA varies from 1 in 100 to about 1 in 6 depending
upon the level of compromised immunity, the environmental ex-
posure and preventative measures taken which can include pro-
tected isolation with filtered air and antifungal prophylaxis. The
outcome depends upon the extent of infection, whether diagnosis
is made and treatment with an effective drug is begun early and,
importantly, on whether or not the immune systems begins to re-
cover (Marr 2002; Walsh 2008). Unlike other infectious diseases,
direct demonstration of Aspergillus infection is seldom possible by
culture of sterile body fluids, and obtaining tissue is seldom pos-
sible as it requires lung biopsy which is a difficult and risky proce-
dure; this has hampered proper diagnosis. Recently, advances have
beenmade on several fronts. Firstly, the EORTC/MSG’s published
definitions of invasive fungal disease (IFD) allow for degrees of
certainty of diagnosis: possible, probable and proven (Ascioglou
2002; De Pauw 2008). Demonstration of fungi in diseased tissue
is still required for a proven diagnosis of IFD. Unfortunately, ob-
taining tissue from a live patient is seldom feasible because of the
risks posed to the patient. Definitions of invasive fungal infection
were devised in 2002 and revised in 2008 to focus on fungal dis-
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ease (Table 1). These are based on host factors, radiological fea-
tures and mycological evidence. Probable and possible cases have
to satisfy the same host and radiological criteria and they are only
distinguished by the presence or absence of mycological evidence.
Biomarkers have potential to detect infection before development
of overt disease, allowing treatment to be initiated at an earlier
stage.
These definitions were only made possible by other developments
in the field. Computer assisted tomography (CT scan) became
more widely available and allows lesions consistent with pul-
monary iA to be detected at an early stage. This offered the possi-
bility of performing bronchoscopy to obtain bronchoalveolar fluid
in which to detect fungus by microscopy and culture. However
the technique is not without risk and cannot always be performed
when required. By contrast, blood is readily available which opens
up the possibility of looking for fungi in an indirect fashion by
detecting fungal cell components including the galactomannan
(GM) of the cell wall of Aspergillus species (Leeflang 2008). The
EORTC/MSG definitions help integrate all the clinical and lab-
oratory information available in terms of host factor such as neu-
tropenia, clinical features such as pulmonary nodules and myco-
logical evidence such as detection of GM to allow a level of cer-
tainty of diagnosis to be assigned. These definitions have been
adopted widely by government agencies such as the European
Medicines Agency and the Food and Drug Administration of the
USA for evaluating antifungal drug products and diagnostic tests,
as well as by the scientific and medical community at large for
investigating epidemiology and auditing antifungal stewardship.
There are circumstances when a host factor is present - for instance
receipt of an allogeneic HSCT - and mycological evidence exists
- such as Aspergillus being recovered from pulmonary secretions -
without evidence of active disease. This may represent infection
before disease becomes manifest. The range of potential drugs cur-
rently available allows treatment to be given for prevention (pro-
phylaxis), for unexplained fever when IFD cannot be ruled out
(empirical therapy), on the basis of non-specific clinical features
or mycological evidence (pre-emptive therapy) and for possible,
probable and proven IFD (directed therapy). However, the ability
to identify who needs treatment, when, and with what, is suffi-
ciently unreliable that many physicians continue to treat empiri-
cally. Not only does this lead to unnecessary costs but it is also not
clear how many people are helped or harmed by this approach.
Consequently there is an urgent need for new diagnostic tools and
an assessment of their utility in the clinic.
Index test(s)
There are few direct diagnostic tests and those that are available
are limited by the difficulties in obtaining tissue specimens to al-
low culture, microscopy and histology (Chamilos 2006). Blood
in its various forms - whole blood, plasma and serum - is readily
available, but only tests for antigens such as GM and beta-d-glu-
can have been deemed acceptable to support a diagnosis (Leeflang
2008; Pfeiffer 2006; Senn 2008). In neutropenic patients, pul-
monary abnormalities consistent with invasive aspergillosis, such
as nodules, often surrounded by a ’halo sign’, can be detected using
high-resolution computed tomography (Greene 2007). However,
the ’halo sign’ is transient and only detectable during early invasive
aspergillosis, after which radiological signs become non-specific or
appear too late to be therapeutically useful (Caillot 2001). Radio-
logical signs also herald established disease so the opportunity to
intervene early has been lost.
Molecular methods, such as the PCR, have being investigated in
order to improve the diagnosis of IA (Donnelly 2006; Mengoli
2009; White 2010 ). PCR can amplify a single or a few copies of
target DNA allowing target detection with great sensitivity and
specificity. Moreover it can be quantitative, using the procedural
variant called real-time PCR (qPCR). The sensitivity is based on
the enormous potential for DNA target (the “amplicon”) ampli-
fication due to repeated cycles of the polymerase reaction, where
every cycle doubles the DNA sequence of interest. Real-time PCR
continuously monitors the amplification of target DNA at every
cycle. The threshold cycle number (preferred term Cq) is when
the amplicon becomes detectable as an exponentially increasing
signal, exceeding the background threshold, and is proportional to
the amount of starting DNA in the reaction. A high initial DNA
concentration will require fewer cycles to reach the threshold and
has a lower cycle threshold value. The specificity of PCR resides in
theDNAoligonucleotides used as primers, allowing the terminally
stable variant of the enzyme DNA polymerase to initiate sequence
duplication. These primers join to the DNA target (“annealing”)
in a very stringent way, allowing only minimal misfit possibility.
Moreover, in real time PCR (RT-PCR), the use of reporter probes,
hydrolysis probes or molecular beacons that bind to the central
part of the target sequence increase the assay’s specificity.
PCR has an enormous potential for diagnosing infectious diseases,
particularly where traditional culture methods are less effective.
The fungal genus Aspergillus is a good example of this kind of ap-
proach. The recovery of Aspergillus from blood cultures is rarely
achieved even in overwhelming infection. Unlike the enzyme-
linked immunosorbent assay (ELISA) test for GM, no commercial
PCRhas been validated for use on blood specimens, although stan-
dards for PCR performance have been developed. PCR based tests
on blood specimens have gained popularity as the platforms be-
comemore automated and extractionmethods and targets become
commercially available (White 2010). However the technique was
not included in either the original or the revised EORTC/MSG
definitions because it had not been validated or standardised at
that time. The European Aspergillus PCR Initiative (EAPCRI) was
founded to address the issue of standardisation of PCR-based di-
agnostics for IA. It has published studies describing the critical
stages in DNA isolation from blood samples (White 2010), and
on the critical characteristics of a standardized Aspergillus PCR
assay. These studies allied to the standardization of qPCR assays
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described in the MIQE (minimum information for publication
of quantitative real-time PCR experiments) guidelines. Bustin et
al. (Bustin 2009) have helped pave the way for reliable and robust
PCR assays for the diagnosis of IA in the clinical setting.
Clinical pathway
The range of antifungal drugs available allows treatment to be
given for prevention (prophylaxis), for unexplained fever when
IFD cannot be ruled out (empirical therapy), on the basis of non-
specific clinical features ormycological evidence (pre-emptive ther-
apy) and for possible, probable and proven IFD (directed therapy).
However, many physicians persist in treating empirically, as the
identification of who needs treatment, when, and with what, is
uncertain. This may lead to unnecessary treatment, which incurs
costs, and may or may not be harmful to some people. Diagnostics
tests can be used to establish a diagnosis but can also be used to rule
out a diagnosis. This is particularly useful for people at risk of IA
where a highly sensitive test can deliver a high negative predictive
value for disease, allowing empirical therapy to be safely withheld
even on the basis of a single test. Conversely, a high positive pre-
dictive value is required to rule in the diagnosis. The use of PCR
as a screening tool differs fundamentally from its use as confirma-
tion of the diagnosis. Therefore, if prevalence is low (i.e., < 10%),
invasive aspergillosis can be ruled out during the risk period for
as long as any single PCR test is negative and, of course, there are
no clinical signs of disease. Conversely, two or more PCR positive
results could be used for mycological confirmation to allow a case
of possible IA to be upgraded to probable IA.
Clinical pathways of managing patients can vary according to the
risk of IA. High risk patients may be screened using GM and
or PCR and positive results may trigger an intensive diagnostic
workup with CT scanning and bronchoalveolar lavage (BAL) to
look for disease (diagnostic driven) or used to initiate antifun-
gal treatment to prevent development of disease (pre-emptive).
Screening may occur throughout the period of risk or only when
people develop fever. Alternatively patients may be tested when
they develop symptoms suggestive of disease to confirm diagnosis.
Rationale
There is no single assay that has been validated for the early diag-
nosis of IA. Non-culture based methods, such as serial GMELISA
screening, hold most promise in establishing early diagnosis and
may result in improved outcomes, but clinical utility is not yet
established. Moreover, newer methods such as PCR are being in-
vestigated (Donnelly 2006). The utility of PCR as either a screen-
ing tool or a confirmatory test will depend on the population in
which it is used. Prevalence of disease, use of prophylactic or em-
pirical antifungal agents, availability of protective environments
and other diagnostic tests will all influence how the test is used in
clinical practice. It is not the aim of this present analysis to establish
clinical outcomes but evaluate diagnostic accuracy so that rational
use of PCR testing can be applied to different populations.
O B J E C T I V E S
To provide an overall summary of the diagnostic accuracy of PCR
based tests on blood specimens for the diagnosis of IA in the
immunocompromised host.
Secondary objectives
When studies included in the analysis also compared the diagnostic
performance of PCR techniques and the GM ELISA assay, we
comparatively evaluated the diagnostic performance of PCR based
tests and GM ELISA assays. However, since the objective of this
review is not to identify all studies dealing with GM ELISA assays
and IA, only those within the study comparison were included in
the review.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies using PCR techniques on blood specimens
for analysis if they:
1. compared the results of PCR tests with the diagnosis made
following the published case definition criteria for invasive fungal
disease proposed by the EORTC/MSG or, for studies published
before the publication of these criteria in 2002, used comparable
criteria as a reference standard (Ascioglou 2002; De Pauw 2008);
2. reported data on false-positive, true-positive, false-negative
and true-negative results of the diagnostic tests under
investigation separately; and
3. evaluated the tests prospectively in a cohort of people from
a relevant clinical population, defined as a group of individuals at
high risk of IA.
We classified studies, on the basis of the samplingmethod, as being
consecutive or non-consecutive. We regarded studies evaluating
specimens from a group of people known to have aspergillosis, and
from a separate group of subjects without evidence of disease, as
case-control studies (Lijmer 1999). These studies were included in
the systematic review but excluded from the quantitative analysis.
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Aspergillus contamination and false positive PCR resultswith bron-
choalveolar lavage (BAL) and sputum samples can follow inhala-
tion of airborne spores or colonization of the lung (Lewis White
2006). Moreover, BAL is an invasive procedure performed only
to confirm the aetiology in a subset of cases that already meet the
clinical definitions of IA. Thus, to avoid bias related to the patient
selection and specimen type, we analysed only studies evaluating
PCR on blood, with exclusion of studies that analyse the accuracy
of PCR tests on BAL only.
Participants
Patients at risk of IA, including neutropenic cancer patients and
HSCT or solid organ transplant recipients.
Index tests
PCR methods on blood specimens (whole blood or serum). We
considered different DNA extraction methods and PCR methods
(e.g., nested, ELISA, qPCR).
Target conditions
The target condition of this review is IA (systemic aspergillosis).
Reference standards
Definitions for invasive fungal disease were first published in 2002
by the EORTC/MSG (Ascioglou 2002) and were revised in 2008
(De Pauw 2008; Table 1). These were used as a reference standard
and comparable criteria were used for studies published before the
publication of the definitions in 2002. The EORTC/MSG defi-
nitions divide the patient population into four categories: people
with proven IA, people with probable IA, people with possible IA,
and people without IA. In accordance with the previous Aspergillus
review on Aspergillus GM detection (Leeflang 2008), sensitivity
and specificity were assessed in each study considering the proven
and probable cases of IA as having the disease, and the cases of
possible IA and no IA as not having the disease.
Search methods for identification of studies
The search strategies for MEDLINE and EMBASE are listed in
Appendix 1.
Electronic searches
We searched the following electronic databases to identify reports
of relevant studies:
• MEDLINE, through Ovid (1946 to June week 2, 2015).
• EMBASE, through Ovid (1980 to June week 2, 2015).
• LILACS (1982 to June 2015).
• Database of Abstracts of Reviews of Effects to June 2015.
• Health Technology Assessment database to June 2015.
• Web of Science to June 2015.
Searching other resources
We also searched for unpublished material on Scopus (http://
www.scopus.com). We checked the reference lists of all the studies
identified by the above methods and contact other authors and
trialists in the field.
Data collection and analysis
Selection of studies
Two review authors (PD, RB) independently assessed the abstract
(if available) of each reference identified by the search against
the inclusion criteria. Any disagreements that arose were resolved
through discussion and consensus with a third author (MC). We
retrieved those references that potentially met the inclusion crite-
ria (based on their abstract or title) in full for further independent
assessment.
Data extraction and management
We extracted the following data from each included study:
• Study design.
• Study population.
• Reference standard and performance of the reference
standard.
• Performance of the index test.
• Technical details of the PCR methods used, including
genetic target of PCR and nucleotide probe sequence, and any
PCR testing methods; we classified the diagnostic modalities
using PCR assays according to the sampling methods and how
these relate to the definition of a positive result, namely either
positive PCR in at least two consecutive blood samples drawn
from the same patient, or a single sample yielding a PCR positive
result. When we compared PCR based tests to GM, we assessed
whether authors explicitly mention the exclusion of the GM
ELISA test from the reference test definition (EORTC/MSG
criteria). In this case, we performed a direct comparison of the
index test and the comparator evaluated in the same study
population towards the reference standard.
• QUADAS-2 items.
• Data for two-by-two table (false-positive, true-positive,
false-negative and true-negative results of the diagnostic tests
under investigation and reference standard).
Two review authors (RB, CM) extracted the data. Disagreements
were resolved by discussion.
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Assessment of methodological quality
Assessment of the quality of diagnostic accuracy studies, as rec-
ommended in STARD (Standards for Reporting of Diagnostic
Accuracy), is of absolute relevance in systematic reviews (Bossuyt
2003; Reitsma 2009; Whiting 2004). For this purpose, we used
the QUADAS-2 tool , the current version of QUADAS that has
been adopted for use by theCochrane Collaboration and is recom-
mended for use in all Cochrane diagnostic test accuracy reviews
to evaluate the risk of bias and applicability of primary diagnos-
tic accuracy studies. Pairs of authors independently assessed the
methodological quality of the studies included, and disagreement
were resolved by consensus with all of the authors.
QUADAS-2 consists of four key domains:
• patient selection;
• index test;
• reference standard;
• flow and timing.
Each is assessed in terms of risk of bias and the first three in terms of
concerns regarding applicability. Signalling questions are included
to assist in judgements about risk of bias. Risk of bias is judged as
“low”, “high”, or “unclear”. If all signalling questions for a domain
are answered “yes” then risk of bias can be judged “low”. If any
signalling question is answered “no” this flags the potential for
bias. The “unclear” category is used only when insufficient data
are reported to permit a judgment.
Tabular and graphical displays are used to summarise QUADAS-2
assessments. We did not calculate a summary score estimating the
overall quality of an article, since their interpretation is problematic
and potentially misleading (Whiting 2005).
The items of the QUADAS-2 tool and their interpretation are
reported in appendix (Appendix 2).
Statistical analysis and data synthesis
The values of sensitivity and specificity are automatically com-
puted in RevMan 2014. Summary positive (LR+) and negative
(LR-) likelihood ratios, and summary diagnostic odds ratio (DOR)
were obtained from the bivariate analysis (see below). We evalu-
ated different interpretive criteria for a PCR positive result in the
two-by-two table, namely a single positive PCR result and two
positive PCR results. We have presented individual study results
graphically by plotting the estimates of sensitivity and specificity
(and their 95% confidence intervals (CIs)) in both forest plots and
receiver operating characteristics (ROC) space.
The diagnostic accuracy indexes and related 95% CIs were com-
pared when studies compared PCR test and serum GM to the
standard reference. The comparative analysis was undertaken by
adding a binary covariate to the bivariate model.
We assessed the operating point sensitivity and specificity of the
diagnostic test under scrutiny by a bivariate random-effects ap-
proach (Reitsma 2005). The original method was modified by
using a random-effects bivariate logistic model (Chu 2006). The
same procedure permits generation of a hierarchical summary re-
ceiver operating characteristic (HSROC) model (Rutter 2001).
The parameters of the bivariate distribution can also be used to
obtain a HSROC curve. Indeed, the bivariate analysis and the
HSROC method without covariates are different parameteriza-
tions of the same model (Harbord 2007). These methods allow
the meta-analysis of sensitivity and specificity in a single model,
incorporating the amount of correlation between sensitivity and
specificity across studies. Moreover, the random-effects approach
allows the multilevel (within and between study) structure of the
sources of variation to be coped with. The results of the bivari-
ate model can be used to calculate likelihood ratios. To calculate
(negative) predictive values, an estimate of prevalence in addition
to values of sensitivity and specificity is required. One can then
apply a Bayesian approach to obtain predictive values from these
three parameters. Bivariate analysis was performed on STATA 11
software.
Investigations of heterogeneity
We assessed heterogeneity by visual inspection of forest plots of
sensitivity and specificity, and through visual examination of ROC
plot of the raw data. Heterogeneity was further investigated, ex-
ploring the effects of several study-level covariates. For this, we per-
formed a multilevel mixed-effects logistic model using the proba-
bility of test positivity as a dependent variable; the group variable
was the study, and the disease status was the first explanatory vari-
able. This basic model admitted in turn several additional covari-
ates. When available, we examined the following covariates:
• Distinctive groups of patients.
• Study size (< or > 100 patients).
• Children versus adults.
• Use of antifungal prophylaxis active against Aspergillus
species.
• Variation in PCR techniques (RT-PCR versus other PCR
methods).
• a single or two positive assay results requirement to define
the test as positive.
• Quality item (e.g., blinding of the index test, blinding of
the reference test).
We included the interaction between the disease status and the
additional covariate into the model as well.
R E S U L T S
Results of the search
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Of the 1672 references identified, we selected 155 potentially rele-
vant citations (Figure 1). After screening titles and abstracts, we se-
lected 57 articles for full-text review.Of these, we excluded39 stud-
ies for various reasons: patients were selected retrospectively in four
studies (Auberger 2011; Bretagne 1998; Cesaro 2008; Challier
2004); 14 studies did not provide sensitivity and/or specificity
data for 2 x 2 tables (Adhurti 2011; Armenian 2009; Badiee 2008;
Badiee 2009; Bernal-Martinez 2011; Blennow 2010; Bucheidt
2004; Hasseine 2010; Hebart 2000; Kawazu 2004; Klingspor
2006; Lass-Florl 2001;Morrissey 2013; Teifoori 2011); eight were
case-control studies (Bucheidt 2001; Bu Rong 2005; Kami 2001;
Li 2013; Millon 2011; Scotter 2005; Skladny 1999; Springer
2013); two studies included BAL only (Bolehovska 2006; Jones
1998); one study included a subset af a previous (AMBILOAD)
trial (Hummel 2010); the index test was inappropriate in five
studies (Chryssanthou 1999; Halliday 2005; Jordanides 2005;
Nakamura 2010; Yoo 2005); the reference standard was inappro-
priate in three studies (Johnson 2012; Mandhanija 2010; Teifoori
2011); two studies were in Chinese (Liu 2005; Sun 2010). There-
fore, 18 studies published between 2000 and 2013 met the inclu-
sion criteria and were included in the meta-analysis (Badie 2010;
Barnes 2009; Cuenca-Estrella 2009; da Silva 2010; El Mahallawy
2006; Ferns 2002; Florent 2006; Halliday 2006; Hebart 2000a;
Hummel 2009; Landlinger 2010; Ramírez 2009; Rogers 2013;
Springer 2011; Suarez 2008; Sugawara 2013; von Lilienfeld-Toal
2009; White 2006). Two studies reported the diagnostic perfor-
mance of PCR performed with different methodologies (Rogers
2013; Suarez 2008), and one in a different patient setting (Rogers
2013). Therefore data were analysed from 22 data sets.
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Figure 1. Study flow diagram.
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The main characteristics of the studies are summarized in the
’Characteristic of studies’ tables. More than 24,000 clinical blood
specimens from 1765 patients at risk of IA were included. The
majority of people had received chemotherapy for a haematologi-
cal malignancy or had been given an HSCT. The PCR techniques
used are summarized in table Table 2. All the selected studies re-
ported the results of a single PCR result, and seven studies reported
using two PCR results (Figure 2; Figure 3). Eight of the studies
included in the analysis also reported results of GM assay. The
study by Rogers et al presented two cohorts of patients (one from
the University Clinic of Wuzburg, and one from Saint James Hos-
pital) according to the PCR test used: Internal Transcribed Spacer
(ITS) qPCR and the 28S nested PCR; Rogers 2013]; the study
by Suarez 2008 et al presented data according to the protocols for
serum processing (large and small volume.
Figure 2. Forest plot of 1 PCR: single positive requirement. The study by Rogers et al. shows separately
data according to PCR test used, and clinical centre participating in the study; in the study by Suarez et al,
data are presented according to protocols for serum processing (large and small volume).
10Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Forest plot of 2 PCR: two positive tests requirements
Thirteen further studies were identified in the latest search
dated June 2015. These have been added to Studies awaiting
classification and will be assessed in a future update.
Methodological quality of included studies
The quality of studies as assessed by the QUADAS-2 tool is sum-
marized in tables and graphs. Figure 4 shows the overall risk of
bias and applicability concerns for the 18 selected studies. Figure
5 presents the quality assessment results for the individual studies.
For all QUADAS-2 domains, most studies were at low risk of bias
and low concern regarding applicability. In the patient selection
domain, all the studies enrolled an homogenous and representa-
tive population of patients at risk of IA; 70% of studies were at
low risk of bias because they enrolled participants consecutively
and avoided inappropriate exclusions. The remaining studies were
graded as being at unclear risk of bias because the manner of pa-
tient selection was not stated.
Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study
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In the index test domain, we considered the majority of studies
to be at low risk of bias (70%) and low concern regarding appli-
cability (80%). The remaining studies were judged to be at high
risk, because the index test was performed knowing the results of
the reference standard, or at unclear risk of bias. In the reference
standard domain, we judged 80% of studies to be at low risk of
bias because it was stated that the reference standard results were
interpreted without knowledge of the results of the index test,
while in the remaining studies it was not specified. Applicability
was of low concern for all studies in the reference standard do-
main. In the flow and timing domain, 75% of studies were judged
to be at low risk of bias because all patients were accounted for
in the analysis, the appropriate reference standard was used, and
information about un interpretable results was provided. We had
nearly complete information for all studies.
Findings
Results of the meta-analysis
Based on 22 data sets (18 primary studies, 19 cohorts), themedian
number of effectives (patients or episodes) per data set was 95
(range 17 to202), and themedianprevalence of provenor probable
IA was 12.0% (range 2.5% to 30.8%); the mean was 108.3 for
effectives, and 12.7% for study prevalence. The sensitivity and
specificity of PCR for the diagnosis of IA varied according to the
interpretative criteria used to define a test as positive. For PCR
assays, the requirement for either one or two consecutive samples
to be positive were evaluated for diagnostic accuracy.With the one
positive requirement, the sensitivity reported in the studies ranged
from 53% to 100%, and specificity from 29% to 97%. With the
2 positive requirements the summary estimates for the sensitivity
ranged from 0% to 92%, and specificity from 75% to 100%. The
mean sensitivity and specificity were 80.5% (95% CI 73.0% to
86.3%) and 78.5% (67.8% to 86.4%) for a single positive result
requirement, and 58.0% (36.5% to 76.8%) and 96.2% (89.6%
to 98.6%) for two positive results requirement. DORs were 15.1
(95% CI 7.9 to 28.6) for a single positive result, and 34.5 (95%
CI 8.2 to 144.2) for two positive results LR+/LR- were 3.7 (2.4
to 5.7)/0.25 (0.18 to 0.35) for a single positive result, and 15.1
(4.9 to 46.1)/0.44 (0.26 to 0.73) for two positive results. When
used in isolation, a single PCR positive test as diagnostic criterion
for IA in a population of 100 people with a disease prevalence
of 13.0% (overall mean prevalence), three people who have IA
would be missed (sensitivity 80.5%, 19.5% false negatives), and
19 people would be unnecessarily treated or referred for further
tests (specificity of 78.5%, 21.5% false negatives). If we use the
two positive test requirement in a populationwith the same disease
prevalence, it would mean that six IA people would be missed
(sensitivity 58.0%, 42.1% false negatives) and three people would
be unnecessarily treated or referred for further tests (specificity of
96.2%, 3.8% false negatives).
Heterogeneity
The appearance of the forest plots for PCR show a large disper-
sion of diagnostic indexes at study level; this was more apparent
for specificity using the single positive requirement, and for sen-
sitivity using the two positive requirement. Visual inspection of
the prediction ellipses in the bivariate analysis show a large area
occupying most of the full probabilistic space; the degree of ec-
centricity was more pronounced in the specificity direction for a
single positive requirement, and in the sensitivity direction for two
positive requirement (Figure 2; Figure 3).
Heterogeneity was investigated by subgroups analyses.
HSROC analysis and bivariate approach
Graphs (ellipses) of bivariate models for the 2 different criteria
for PCR positivity are shown in Figure 6. Unpaired studies were
excluded for the evaluation of the differential effect of the single
positive/two positive criterion. The number of studies included
in the paired analysis was reduced to seven, corresponding to 11
comparisons of PCR test (each paired for single positive and two
positives criteria; Badie 2010;Cuenca-Estrella 2009; Florent 2006;
Halliday 2006; Rogers 2013; Springer 2011; Suarez 2008).
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Figure 6. Bivariate analysis of the sensitivity and specificity of the PCR as a diagnostic tool for Aspergillus
invasive infection. Two diagnostic criteria are compared: single positive PCR result (“1 pos”) versus ≥ two
positive consecutive PCR results (“2 pos”). The square dots indicate the means (“central point”). The smaller
ellipses indicate the 95% confidence area of the means, the larger ellipses indicate the 95% forecast areas for a
new observation. The hierarchical summary receiver-operator curves are depicted as well.
When sensitivity and specificity data from the bivariatemodel were
compared, changing the positive results requirement from 1 to 2
increased significantly the specificity (from 78.5% to 96.2%, P
value = 0.0000); by contrast, the sensitivity decreased significantly
from 80.5% to 58.0% (P value < 0.0001). The joint effect on
sensitivity and specificity was also significant (P value < 0.0001).
The DORs changed from 15.1 with a single positive assay to 34.5
with two positive assays.
Subgroups analysis and bivariate analysis with covariates.
We carried out a subgroup analysis of adult and paediatric studies
(El Mahallawy 2006; Halliday 2006; Hummel 2009; Landlinger
2010). The diagnostic yield did not differ significantly between
adult and paediatric studies. However, the limited number of pae-
diatric studies does not allow firm conclusion to be drawn regard-
ing the diagnostic performance of PCR in paediatric patients. We
also performed a subgroup analysis according to study size. Stud-
ies were defined as small or large size according to the number of
enrolled people (< or > 100). Likewise study size did not have a
significant impact on performance of PCR test.
A subgroup analysis of studies endorsing 2002EORTCcriteria (10
studies: El Mahallawy 2006; Ferns 2002; Florent 2006; Halliday
2006;Hebart 2000a; Hummel 2009; Ramírez 2009; Suarez 2008;
von Lilienfeld-Toal 2009; White 2006) or 2008 criteria (seven
studies: Badie 2010; Barnes 2009; Cuenca-Estrella 2009; da Silva
2010; Rogers 2013; Springer 2011; Sugawara 2013) was also per-
formed using the bivariate method and considering the results of
PCR testwith the single positive criterion.One study stated the use
of EORTC criteria but did not mention which criteria were em-
ployed (Landlinger 2010). Lower sensitivity and specificity values
were found for studies using 2008 criteria compared to those using
2002 criteria (76.18% and 74.44% versus 82.82% and 79.50%,
respectively), but these differences were probably driven by the
low estimates of diagnostic accuracy found in some of the 2002
studies (Rogers 2013; Springer 2011).
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Eleven studies used antifungal prophylaxis in the entire population
under investigation (Badie 2010; Barnes 2009; Cuenca-Estrella
2009; Ferns 2002; Florent 2006; Halliday 2006; Hebart 2000a;
Rogers 2013; Springer 2011; Sugawara 2013; White 2006), four
studies did not (da Silva 2010; El Mahallawy 2006; Suarez 2008;
von Lilienfeld-Toal 2009), one study used prophylaxis (antifun-
gal agent not specified) in a subset (50%) of patients (Landlinger
2010), and two studies provided no details on the use of prophy-
laxis (Hummel 2009; Ramírez 2009). Fluconazole was used as
prophylaxis in four studies (Badie 2010; Halliday 2006; Hebart
2000a; Springer 2011), seven studies used prophylaxis with an-
tifungal agents active against Aspergillus (itraconazole, voricona-
zole, amphotericins or caspofungin; Barnes 2009; Cuenca-Estrella
2009; Ferns 2002; Florent 2006; Rogers 2013; Sugawara 2013;
White 2006). To evaluate the impact of prophylaxis on diagnos-
tic accuracy of PCR, we used a mixed-model logistic analysis us-
ing the probability of the index test positivity as the dependent
variable. When examining data under the criterion “single posi-
tive”, the prophylaxis produced a large reduction in specificity (-
26.7%), whereas the change of sensitivity was small (- 2.9%), and
not excluding the zero. When examining data under the criterion
“two positives”, the logistic regression was unfeasible because all
“no prophylaxis” studies had no false positive results. When the
analysis was conducted considering only the subgroup of seven
studies with anti-Aspergillus prophylaxis versus “no-prophylaxis”
studies (includingfluconazole prophylaxis studies), therewas again
a reduction in specificity (- 20.7%), and a small, not statistically
significant change in sensitivity (- 5.9%).
The PCR methods varied notably. Some studies were based on
gel electrophoretic visualization after proper staining of the ampli-
cons, whereas others were based on automated procedures, as real-
time PCR, with substantial differences regarding the threshold of
detection. We relied on the reported positive/negative results only,
and the possible cut-point/threshold variation across studies was
not considered. When the accuracy of the real-time PCR (quan-
titative PCR) was compared to other PCR methods, no signifi-
cant effect was detected on sensitivity or specificity, separately or
jointly.
Quality items that did have an effect on sensitivity or specificity
were blinding of the index test (13% decrease in sensitivity and
9.4% decrease in specificity; P value = 0.0099) and blinding of
the reference standard (10.6% decrease in sensitivity and 14.7%
decrease in specificity; P value = 0.0087). In other words, failure
of blinding produced a spurious increase in overall accuracy.
Predictive values
Positive and negative predictive value (PPV andNPV, respectively)
of the Aspergillus PCR detection are shown in Figure 7. The pre-
dictive values were calculated by applying the Bayes rule. With a
mean prevalence of invasive aspergillosis of 13%, the PPV is 36%
with a single positive test criterion, and 70 % with two positive
tests criterion; for NPV these figures were 96% and 94%, respec-
tively.
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Figure 7. Predictive values. Positive and negative predictive value (PPV and NPV, respectively) of the
Aspergillus PCR detection test (y-axis) as a function of the prevalence of the disease, invasive aspergillosis (x-
axis). The curves are related to the diagnostic criterion (a single positive result or two consecutive positive
PCR results). The PVs were calculated by applying the Bayes rule. The mean prevalence of invasive
aspergillosis (13%) is indicated by the vertical dashed line. It corresponds to PPV1 = 36%, NPV1 = 96%, PPV2 =
70%, NPV2 = 94%.
Comparison between PCR techniques and GM assay
Nine studies (Barnes 2009; Cuenca-Estrella 2009; da Silva 2010;
Florent 2006;Rogers 2013; Springer 2011; Suarez 2008; Sugawara
2013; White 2006) also evaluated GM assay, but in all studies but
one GM was part of the reference standard (Suarez 2008). Thus,
to avoid incorporation bias, data of GM assay were not compared
to PCR, and not included in the current review.
In the study by Suarez 2008, sensitivity and specificity were 100%
and 96.7% for RT-PCR using large sample volume (LSV), and
88.2% and 95.8% for GM. Thus the overall performance of RT-
PCR using LSV was consistently higher than that of GM.
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Summary of findings
INTERPRETATIVE CRI-
TERIA TO DEFINE
THE TEST POSITIVE
EFFECT (95% CI) NO. STUDIES PREVALENCE: MEAN (95%
CI)
WHAT DO THESE RESULTS
MEAN
1 SINGLE PCR SPECI-
MEN
sensit ivity: 80.5% (72.
9% to 86.3%)
specif icity: 78.5% (67.
8% to 86.4%)
17 studies 13.3% (11.9% to 14.8%) With a prevalence of 13%,
13 out of 100 pat ients will
develop IA. Of these, 3 will
be missed by a single PCR
test (19.5%of 13); of the 87
pat ients without IA, 18 will
have a false posit ive result
of the PCR test; repeat ing
the test will reduced signif -
icant ly rates of false posi-
t ive results
≥2 PCR SPECIMENS sensit ivity: 57.9% (36.
5% to 76.8%)
specif icity: 96.2% (89.
6% to 98.6%)
8 studies 14.0% (12.3% to 15.9%) With a prevalence of 14%,
14 out of 100 pat ients will
develop IA. Of these, 6 will
be missed using the 2 posi-
t ive PCR test (42.0% of 14)
; of the 86 pat ients without
IA, 3 will have a false posi-
t ive result of the PCR test
The PCR methods varied notably across studies. Several covariates (in part icular, the adopt ion of ant if ungal prophylaxis and
blinding to the reference test or index test) were found to substant ively af fect the accuracy indexes under evaluat ion,
mainly sensit ivity and specif icity.
CI: conf idence interval
IA: invasive aspergillosis
PCR: polymerase chain react ion
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D I S C U S S I O N
Summary of main results
Eighteen primary studies, corresponding to 19 cohorts and 22 data
sets, were included in the meta-analyses, with a mean prevalence
of IA (proven or probable) of 13.3%. The majority of patients
had received chemotherapy for a haematological malignancy or
had been given a hematopoietic stem cell transplant. Several PCR
techniques were used among the included studies. The sensitivity
and specificity of PCR for the diagnosis of IA varied according to
the interpretative criteria used to define a test as positive. For PCR
assays, the requirement for either one or two consecutive samples
to be positive were evaluated for diagnostic accuracy. The mean
sensitivity and specificity were 80.5% (95% CI 72.9% to 86.3%)
and 78.5% (67.8% to 86.4%) for a single positive test result, and
57.9% (36.5% to 76.8%) and 96.2% (89.6% to 98.6%) for two
positive test results. The findings indicate that PCR shows mod-
erate diagnostic accuracy when used as a screening test for inva-
sive aspergillosis in high risk patient groups. Several covariates (in
particular, the adoption of antifungal prophylaxis and blinding to
the reference test or index test) were found to substantially affect
the accuracy indexes under evaluation, particularly sensitivity and
specificity. The uneven distribution of these covariates may ex-
plain, at least partly, the large heterogeneity found in this analysis
The subgroup analyses suggest that antifungal prophylaxis might
impair performance and these conclusions may not be applicable
to patients on concurrent antifungal therapy.
Strengths and weaknesses of the review
The findings of this review are based on comprehensive search-
ing, strict inclusion criteria, and standardized data extraction. The
strength of our review is that it enables an assessment of the diag-
nostic accuracy of PCR for detection of IA in a homogenous popu-
lation of patients at risk of IA. The strict inclusion criteria (cohort
of consecutive patients, including neutropenic cancer patients and
hematopoietic stem cell or solid organ transplant recipients) were
used to cover the spectrum of diseases likely to be encountered in
the current or future use of this diagnostic test.
We only included studies that used the EORTC/MSG criteria or
a similar reference standard. Differences in the reference standard
may have contributed to differences we found in the distribution
of patients with probable, possible and no invasive aspergillosis but
not proven disease as this relies on demonstration of the fungus in
tissue. For instance the clinical features in the revised definitions
are based solely on radiological evidence of IA whereas the origi-
nal 2002 definitions also included minor signs such as fever and
cough as evidence of disease. Consequently employing the revised
definitions to cases classified as possible IA by the 2002 definitions
would only be retained as such if there was radiological evidence.
Applying the 2008 definitions would have a similar effect on prob-
able IA for the same reasons.
The impact of empirical antifungal usage has not been analysed.
It is likely that PCR can detect infection before overt disease is
radiologically detectible. Consequently, people with positive re-
sults who did not meet the criteria for proven or probable disease
could have had early infection that resolved either with empirical
or pre-emptive antifungal treatment or as a result of resolution of
the underlying immunosuppression.
The lack of direct comparisons with other biomarkers including
GM and beta-D-glucan could be a further shortcoming. Looking
at our findings and at those of other reviews, the performance of
PCR test is comparable to that reported for GM and superior to
beta-D-glucan. It is likely that combinations of different biomark-
ers will provide the optimal diagnostic performance. Also it was
difficult to distinguish between using PCR for screening purposes
and for confirming the diagnosis as these are associated with low
and high a priori likelihood respectively. Furthermore, screening
requires testing at regular intervals during the period of risk (typi-
cally every 3 to 4 days) whereas tests for confirming the diagnosis
of IFD will only be done once.
The molecular basis for azole resistance has been described, and
the ability to detect Aspergillus DNA also raises the possibility of
rapid detection of antifungal resistance using the same specimen.
This could optimise patient management further and should be
explored in future studies.
Applicability of findings to the review question
We noted that most studies performed PCR in high-level, refer-
ence laboratories. It is not clear whether intermediate/peripheral
laboratories might be settings that match the review question due
to the lack of commercially available PCR tests. Much has been
done by the EAPCRI to establish a standard for PCR that should
help laboratories offering the test (www.eapcri.eu). However in-
corporating PCR into routine practice also requires an explicit pro-
tocol indicating who should be tested, when and how frequently,
as well as what action should be taken in the event of a given re-
sult. Moreover the process needs to be completed within 24 hours
so that the results can be used to best advantage by the clinician.
This requires an explicit care plan or pathway, a multidisciplinary
approach and a clear understanding between the clinic and labo-
ratory to ensure a smooth turnaround.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The findings indicate that PCR screening tests show moderately
good diagnostic accuracy when used as screening tests for IA in
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high-risk patient groups. However, for a screening strategy, with
the low prevalence of IA in the observed population and a low
pre-test probability of disease, themoderate sensitivity of the PCR
is sufficient to ensure a good negative predictive value, such that
disease can be confidently excluded and the need for empiric ther-
apy avoided. As such, screening strategies could replace empirical
antifungal therapy in selected high-risk patients. Consecutive pos-
itives show moderate specificity in the diagnosis of IA and could
be used to trigger radiological and other investigations or for pre-
emptive therapy in the absence of specific radiological signs when
the clinical suspicion of infection is high. The subgroup analyses
suggest that antifungal prophylaxis could impair performance and
these conclusions may not be applicable to people on concurrent
antifungal therapy. With the observed prevalence of disease (13
%), repetition of the PCR test increase considerably the positive
predictive values, with a modest decline of the negative predictive
values. Therefore, the repetition of the PCR assay is recommended
in order to increase the diagnostic accuracy.
Implications for research
It is clear that PCR holds a lot of promise as a useful test for detect-
ing Aspergillus infection although the diagnostic accuracy might
be improved further by combining the test with other biomarkers
such as GM, and this should be explored in future studies. Fur-
ther validation is also need to determine whether using PCR for
screening high-risk patients could become the standard of care.
Future studies that validate PCR for aspergillosis clearly need to
distinguish between use of the test to screen for the presence or
absence of IA in high-risk patients if there are no signs of illness,
and its use to confirm or exclude the disease when it becomes
manifest. IA can be ruled out during the risk period for as long
as any single PCR test is negative and there are no clinical signs
of disease. Conversely when prevalence of aspergillosis is around
10%, two or more PCR positive results can be used for mycolog-
ical confirmation to allow a case of possible IA to be upgraded to
probable.
The tests need to be incorporated into patient care pathways that
compare prophylactic, empirical, pre-emptive and targeted anti-
fungal drug use looking at impacts on patient management.
It was not possible to investigate the diagnostic utility of combina-
tions of biomarkers (e.g. PCR and GM) because the GM is incor-
porated into the EORTC/MSG definitions and would introduce
incorporation bias. Hence, cases would have to be classified by
omitting GM. Further studies are needed to assess clinical utility
and cost effectiveness.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Badie 2010
Study characteristics Study characteristics
Patient sampling Prospective study, samples collected Sep 2004 - June 2006. Patients with haematological malignan-
cies (who had received chemotherapy)
Patient characteristics and set-
ting
Sample size: 194
Males/females: 133/61
Mean age: 33.7 years (range 14 to 80)
Presentation: patients with haematological malignancies and solid organ transplantation at risk for
IFD
Setting: Nemazi Hospital, Shiraz, Iran
Index tests DNA extracted through lysis of blood and fungal cells (van Burik 1998) followed by purification
using the QIAamp DNA Mini Kit. Standard PCR was used as well as PCR-ELISA. Aspergillus
specific assays (Aquirre 2004). Presence or absence of bands indicated a positive result; positive
results were retested with species specific probes
Target condition and reference
standard(s)
Patients were evaluated for IA; patient samples (urine, cerebrospinal fluid, pleural and abdominal
tap, BAL and sputum) were examined for signs of infection. Cases of IA were defined according to
the EORTC/MSG 2002 criteria
Flow and timing Samples were collected from 209 patients between September 2004 and June 2006; 985 samples
collected from 194 patients were analysed. Blood samples (EDTA) were collected once per week
and frozen prior to analysis. Patients were excluded if they did not attend follow-up for more than
two weeks. No indication that patients with possible IA were excluded from 2x2 analysis
Comparative
Notes This study describes the performance of standard PCR and PCR-ELISA
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Badie 2010 (Continued)
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
High High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
No
Unclear
Barnes 2009
Study characteristics Study characteristics
Patient sampling Prospective study between October 2005 and March 2006; at risk febrile patients or SCT patients
with graft-versus-host disease
were tested
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Barnes 2009 (Continued)
Patient characteristics and set-
ting
Sample size: 125 patients
Males/females: 1.4/1
Mean age: 56.2 years (range 16 to 83)
Presentation: haematology patients at risk for IFD including SCT, acute myeloid leukemia
Setting: University Hospital of Wales
Index tests DNA extracted from 2ml blood, red cell lysis, white cell lysis, bead beating andMagna Pure (Roche)
DNA purification (White 2006). Nested PCR with second round on lightcycler (Roche) targeting
28S, 60 cycles all together. All positive samples were repeated
Target condition and reference
standard(s)
IFDwas the target condition for PCR assays; GMantigen testing was performed on patient samples,
EORTC/MSG 2008 criteria (including GM) were used to define cases of IFD
Flow and timing 1028 specimens collected from 125 patients over a six month period. 130 patients were screened
but 125 were evaluable. No indication that patients were excluded from 2 x 2 analysis; this analysis
was performed for “single non-reproducible positive PCR”, “Single reproducible positive PCR”
and “multiple positive PCR” results
Comparative
Notes Report examines diagnostic driven care pathway, limited empirical treatment. Data provided for
interpretation of single and reproducible results. Very relevant to this review
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
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Barnes 2009 (Continued)
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Low
Cuenca-Estrella 2009
Study characteristics Study characteristics
Patient sampling Patients with febrile neutropenia considered at risk from IA were studied prospectively between
October 2004 and November 2005
Patient characteristics and set-
ting
Sample size: 83 patients
Males/females: 48/35
Mean age: 52 years
Presentation: patients with haematological malignancies and febrile neutropenia at risk for IA
Setting: Hospital Universitario 12 de Octubre in Madrid, Spain
Index tests DNA extraction: DNA was extracted from the samples using the QiampDNA Mini Kit (Qiagen,
Izasa, Madrid, Spain)
DNA detection: 2 µl of DNA from each sample were used for eachRT-PCR, which contained a final
volume of 20 µl with 3 mM of Cl2Mg, 0.5 µM from each primer, and 0.4 µM of molecular beacon
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Cuenca-Estrella 2009 (Continued)
probe. Preincubation was at 95°C, followed by 45 denaturation cycles (15 s at 95°C), annealing (30
s at 56°C), and extension (5 s at 72°C). Each experiment was run twice
Definition of positive assay: the results were considered positive when an exponential increase in
fluorescence was detected compared with that of the negative controls before cycle 40 of amplifica-
tion. The detection limit was 10 fg of DNA per µl of sample (cycle 42 of amplification)
Aspergillus-specific: analyses for at least 1, 2 or 3 positive PCR tests retesting. 2244 specimens tested
Target condition and reference
standard(s)
The definitions of proven, probable and possible IA were set according to the definitions of the
EORTC/MSG. HRCT and GM testing were also performed as a part of reference standard
Flow and timing Four weekly samples (two blood and two serum) were taken during episodes of febrile neutropenia
Time interval sampling: 2004-05
Selection/exclusion for analysis: excluding patient 10, for whom the PCR result was negative, it was
possible to calculate the time gain in diagnosis for the PCR technique compared to that for HRCT
and GM for the other 11patients with IA
Sampling/storage: years (range)
Analysis type: at least 2 consecutive positive PCR results missing/uninterpretable results: N
Comparative
Notes Prophylaxis: itraconazole; proven/probable/possible/no IA: 1/9/2; PCR effectiveness (replica/eluat
into PCR volume): 2 x 2 of 200 µl. The information collected on each patient, as well as the PCR
results, were entered in a database
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
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Cuenca-Estrella 2009 (Continued)
If a threshold was used, was it
pre-specified?
Yes
High Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
da Silva 2010
Study characteristics Study characteristics
Patient sampling From October 2000 to August 2003, 172 patients with haematologic malignancies and 27 patients
receiving high dose chemotherapy in an autologous hematopoietic stem cell transplantation setting
were studied prospectively. All patients were screened by PCR twice a week since admitted in the
ward
Patient characteristics and set-
ting
Patients with haematological malignancies and febrile neutropenia at risk for IA
Median age 50 years
Male/female: 102/70
Setting: Hospital dos Capuchos, Lisbon, Portugal
Index tests Blood samples, BAL samples, fungal DNA extraction and PCR conditions were performed as
described in van Burik 1998. The whole process of amplification was done using Taq polymerase
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da Silva 2010 (Continued)
(Gibco BRL) and pan-fungal primers that bind to the conserved regions of the fungal 18S
rRNA gene sequence. Established PCR negative and positive controls were used in every assay. 1311
blood specimens tested
Target condition and reference
standard(s)
Fungal infections were classified according to EORTC/MSG revised consensus
Flow and timing Peripheral blood samples frompatients were screened twice weekly for bothmethods since admission
to the ward. If a positive value was obtained the patient would be screened every day for 3 consecutive
days in the first week and then twice weekly again
Comparative
Notes The study also evaluated GM assay, but due to incorporation bias (GM is part of the reference
standard), these data were not included in the current review
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
Yes
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da Silva 2010 (Continued)
condition?
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
El Mahallawy 2006
Study characteristics Study characteristics
Patient sampling Febrile, neutropenic paediatric cancer patients were prospectively sampled between April 2003 and
April 2004. Patients were included if they had antibiotic-resistant fever. Patients were given full
diagnostic work-ups for any signs of IFD
Patient characteristics and set-
ting
Sample size: 91 patients
Males/females: 37:25
Mean age: 8 (range 2 to 18)
Presentation: “at risk” for IA including febrile neutropenic cancer patients and fever not responding
to antibiotics
Setting: National Cancer Institute, Cairo University
Index tests Serum samples (unknown volume) were treated with Lyticase, then extracted using QIAamp DNA
Mini Kit (Qiagen), PCR amplified 420 bp products from 18S gene (universal fungal assay). Single
round conventional PCR with 30 cycles. Products detected on agarose gel
Target condition and reference
standard(s)
Target condition was IFD; CT scan, blood culture and Aspergillus antigen detection were used to
aid in defining cases of IFD according to the EORTC/MSG (2002) criteria
Flow and timing 91 patients tested, unknown sample numbers during 1 year period. All patients were included in
2 x 2 analysis to calculate sensitivity, etc
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El Mahallawy 2006 (Continued)
Comparative
Notes Pan-fungal conventional PCR used with low cycles, lack of specific IA information may be a problem
for inclusion
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Low High
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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El Mahallawy 2006 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
Unclear
Ferns 2002
Study characteristics Study characteristics
Patient sampling Ninety-four blood samples from 17 patients at high risk of IA undergoing chemotherapy for acute
leukaemia (10) or undergoing allogenic BMT (7) on the haematology unit at the University College
London Hospital Trust were screened
Patient characteristics and set-
ting
Gender and age: not specified
Setting: University College London Hospital Trust
Index tests Aspergillus DNA, from whole blood samples, was amplified by nested PCR to detect a 135 bp
fragment in the mitochondrial region of Aspergillus fumigatus or Aspergillus flavus (121 bp).
Target condition and reference
standard(s)
IA in haematologic patients. The diagnosis of aspergillosis was classified into proven, probable or
possible on the basis of EORTC/MSG criteria
Flow and timing PCR results were retrospectively compared with clinical data and antifungal treatment
Comparative
Notes None of the 94 samples from the 17 patients were above the cut-off value when tested as serum in
the Platelia Aspergillus antigen ELISA
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Ferns 2002 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Unclear Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Unclear
Were all patients included in the
analysis?
Yes
Unclear
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Florent 2006
Study characteristics Study characteristics
Patient sampling FromApril 2001 throughNovember 2002, all patients (> 15 years) with hematological malignancies
who were routinely screened for GM detection were included in the study. Gender and age were
not specified. Setting was Hopital Saint-Louis and Hotel-Dieu, Paris
Patient characteristics and set-
ting
A total of 201 patients were enrolled in the study and had 256 consecutive episodes of neutropenia
(neutrophil count fewer than 500 cells/mL). During the high-risk periods for infection and until
absolute neutrophil counts increased to greater than 500 cells/mL, all patients were hospitalised in
protected facilities with high-efficiency particulate air filtration associated with laminar air flow for
patients undergoing allogeneic stem cell transplantation
Index tests DNA was extracted from both serum and fungal cultures by use of the QIAamp DNA Mini Kit
(Qiagen), in accordance with the manufacturer’s recommendations. Two negative controls were
used in each DNA extraction experiment. The PCR-ELISA was performed using the serum sample
that was collected for GM detection, which was stored at -20°C until processing. 1205 specimens
tested
Target condition and reference
standard(s)
the criteria proposed by the EORTC/MSGwere used. To evaluate the performance of the GM assay
either alone or in combination with the PCR-ELISA, the results of the GM assay were not included
in the microbiological criteria for the diagnosis of probable IA
Flow and timing Single-positive results were defined as at least a single positive result, and consecutive positive results
were defined as at least two positive results obtained consecutively within 1 week. Thirty-four
patients did not have consecutive serum samples that were collected within 1 week, and they were
excluded from the final analysis. Because of the uncertainty of the diagnosis in patients with possible
IA, 3 separate analyses were performed: the first included only proven and probable IA cases; the
second included proven and probable IA cases, and possible cases were considered to be proven IA
cases; and the third included proven and probable IA cases, and possible cases were not considered
to be IA. Inhibitors were detected in 18 serum samples, and these samples were excluded from the
analysis
Comparative
Notes PCR-ELISA precocity in diagnosing IA was assessed in comparison with the timing of the clinical
suspicion of IA, the results of CT, and histological and microbiological criteria as defined by the
EORTC/MSG
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
37Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Florent 2006 (Continued)
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
Unclear
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Halliday 2006
Study characteristics Study characteristics
Patient sampling Prospective collection of samples from patients undergoing chemotherapy or HSCT who had de-
veloped febrile neutropenia between Aug 2002 and July 2003. Blood samples collected from con-
secutive patients twice weekly; only patients from whom three samples were obtained per febrile
episode were analysed
Patient characteristics and set-
ting
Sample size: 65 patients
Males/females: 23:6
Mean age: 37 (range 16 to 62)
Presentation: Episodes of febrile neutropenia in patients undergoing chemotherapy or HSCT
Setting: Westmead Hospital, NSW, Australia
Index tests Blood collected twice weekly; DNA extracted from 500 µl EDTA blood using the GenElute Mam-
malian Genomic DNA Kit (Sigma-Aldrich) with modified protocol that included RCLB, followed
by lyticase treatment; no bead beating. Conventional nested PCR no qPCR assay modified from
(Skladny 1999). Aspergillus specific targeting 18S. Sensitivity of 10 CFU/ml
Target condition and reference
standard(s)
Target condition was IA, classified according to the EORTC/MSG criteria (2002). IA defined at
the end of “at risk” episodes
Flow and timing 998 blood samples from 65 patients (29 adults and 36 children) were collected between August
2002 and July 2003. Separate 2 x 2 analyses were carried out to calculate sensitivity, etc, with possible
cases excluded, or with possible cases included as true negatives or true positives
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
39Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Halliday 2006 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Hebart 2000a
Study characteristics Study characteristics
Patient sampling Prospective sample collection from patients who had undergone allogenic SCT between 1996 and
1997. Five ml EDTA was collected 2 to 4 times weekly from the time of admission until discharge
or death. Samples from multiple centres were analysed in Tübingen
Patient characteristics and set-
ting
Sample size: 84 patients
Males/females: not specified
Mean age: 35 years (range 17 to 57)
Presentation: patients had undergone allogeneic SCT
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Hebart 2000a (Continued)
Setting: University Hospital Würzburg
Index tests DNA extracted from 5 ml blood as described by Einsele et al 1997 (JCM); PCR targeting 18S
with Aspergillus specific probe (Aspergillus fumigatus, flavus and versicolour) for slot blot testing (not
qPCR)
Target condition and reference
standard(s)
IA was the target condition; cases of proven IA were defined as recovery of Aspergillus from normally
sterile sites, positive culture or demonstration of hyphae from deep tissue biopsy and autopsy
specimens along with clinical symptoms. Probable IA was defined as the presence of clinical signs
and symptoms together with radiographic evidence compatible with IA and isolation of Aspergillus
from respiratory specimens.
Flow and timing 1193 samples from 84 patients collected twice weekly and processed twice weekly. 2 x 2 analysis to
calculate sensitivity, etc. Included all patients (possible was not defined). Parameters were calculated
for both early and late onset IA
Comparative
Notes This study utilises definitions of IA that are pre-EORTC/MSG. Generally seems a compatible study
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
Low Low
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Hebart 2000a (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Hummel 2009
Study characteristics Study characteristics
Patient sampling PCR results from all consecutive patients from three university children’s hospitals investigated
between November 2000 and January 2007 were evaluated in this study
Patient characteristics and set-
ting
The majority of patients had malignant haematological diseases. Patients from three university
children’s hospitals
Index tests AspergillusDNAwas detected in clinical samples by an experimentally and clinically validated nested
PCR assay as described previously (Bucheidt 2001; Bucheidt 2004; Skladny 1999).
Target condition and reference
standard(s)
IA; EORTC/MSG criteria
Flow and timing between November 2000 and January 2007
Comparative
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Hummel 2009 (Continued)
Notes Results of serological diagnostic techniques (GM assay, Platelia Aspergillus enzyme immunoassay;
Bio-Rad) and post-mortem histological examination were included for clinical classifications
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
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Hummel 2009 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Landlinger 2010
Study characteristics Study characteristics
Patient sampling Clinical specimens from consecutive patients were prospectively collected
Patient characteristics and set-
ting
125 paediatric haemato-oncological patients undergoing intensive chemotherapy (65) or allogeneic
stem cell transplantation (60) were analysed during 150 episodes of febrile neutropenia
Index tests Pan-fungal RT-PCR
Target condition and reference
standard(s)
IA; EORTC/MSG criteria
Flow and timing Whenever possible, specimens were collected at first onset of fever, within 48 hours thereafter, and
at subsequent time points in the course of the febrile episode, upon availability
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Landlinger 2010 (Continued)
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Ramírez 2009
Study characteristics Study characteristics
Patient sampling Prospective sampling of “at risk” patients for IFD between June 2004 and July 2006. Samples also
taken from patients for whom confirmation of IFD before, during and after treatment was required
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Ramírez 2009 (Continued)
Patient characteristics and set-
ting
Sample size: 127 patients
Males/females: 64/63
Mean age: 45 years (range 30 to 58)
Presentation: patients at risk for IA and those requiring confirmation of IFD
Setting: Hospital Universitario de Valme, Seville, Spain
Index tests DNA extracted from 5 ml blood (EDTA); used RCLB, glass bead disruption and QiaAmp DNA
Mini Kit. Light cycler assay as described by (Loeffler 2000). Twenty µl PCR included 10 µl template
DNA; 50 cycles; followed by melt-curve analysis. DNA extraction control included, no internal
control
Target condition and reference
standard(s)
IA was the target condition; cases were defined according to the EORTC/MSG criteria (2002)
Flow and timing 948 clinical samples from 127 patients collected between June 2004 and July 2006. Samples pro-
cessed immediately or stored prior to processing. 2 x 2 analysis was not conducted. Study focused
on analytical sensitivity (60 fg Aspergillus DNA, or 5 to 20 conidia); 1% of the samples were PCR
positive
Comparative
Notes This study had 5 proven/probable cases, 17 possible
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
No
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Ramírez 2009 (Continued)
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Rogers 2013
Study characteristics Study characteristics
Patient sampling Consecutive patients at risk of IA. Age not specified
Patient characteristics and set-
ting
Patients undergoing remission-induction chemotherapy for acute leukaemia, lymphoma, or
myeloma, autologous or allogeneic bone marrow or stem cell transplant were eligible for inclusion.
Over the course of the study 146 patients were recruited from Trinity College Dublin & St. James’s
Hospital, Dublin, and 132 from the Department of Internal Medicine, University of Würzburg
Medical Centre, Würzburg, Germany
Index tests ITS qPCR assay targeting the ITS 1/5.8S ribosomal operon was performed as previously described
(Springer 2011)
Target condition and reference
standard(s)
The EORTC/MSG definitions were used for categorization of patients with IFD including IA
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Rogers 2013 (Continued)
Flow and timing Patient blood samples were collected twice weekly; in UKW the EDTA blood samples were logged
and processed prospectively while, in SJH, they were frozen at 80°C and processed in retrospective
batches. DNA extracts were stored at 20°C until they were processed by the second PCR assay
Comparative
Notes GM was part of the EORTC/MSG criteria for IFD
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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Rogers 2013 (Continued)
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Springer 2011
Study characteristics Study characteristics
Patient sampling Consecutive patients at high risk of IA. Five hundred thirty-six specimens from 46 patients at high
risk for invasive fungal infection were collected
Patient characteristics and set-
ting
Patients at risk of IA after allogeneic SCT and patients receiving myeloablative chemotherapy with
an expected duration of neutropenia (leukocyte count of 1,000/L) of at least 10 days. Nineteen
males (mean age 51 years), 17 females (mean age 58 years)
Index tests Quantitative PCR and ITS semi quantitative RT-PCR assay
Target condition and reference
standard(s)
EORTC/MSG criteria
Flow and timing Between January and August 2009, blood samples from patients with a high risk of IFD, together
with clinical data, were collected
Comparative
Notes GM performed as a part of EORTC/MSG criteria for IA
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
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Springer 2011 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Suarez 2008
Study characteristics Study characteristics
Patient sampling All adult patients receiving allogeneic or autologous hematopoietic SCT, or intensive (induction,
consolidation, or salvage) chemotherapy for hematological malignancies were included in the study
Patient characteristics and set-
ting
124 patients (138 treatment episodes) at risk of IA in the adult hematology and bone marrow
transplant unit at Necker-EnfantsMalades hospital, a tertiary-care university hospital (Paris, France)
Index tests RT-PCR on 1342 specimens
Target condition and reference
standard(s)
EORTC/MSG-documented IA. The diagnosis of IA (proven, probable, or possible) was defined for
a given patient as the day on which the first clinical, radiological and/or microbiological EORTC/
MSG criteria, other than a GM-positive result, appeared
Flow and timing This study was conducted prospectively from February 2006 toMarch 2007. The dates of diagnosis
and the dates on which the first positive test results for Aspergillus fumigatus DNA and GM were
recorded.
Comparative
Notes for GM, incorporation bias avoided
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
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Suarez 2008 (Continued)
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Sugawara 2013
Study characteristics Study characteristics
Patient sampling Prospective analysis of consecutive blood samples from patients at risk for IFD
Patient characteristics and set-
ting
51 patients with haematologic disorders at high risk for IFD who were treated at Mie University
Hospital, Japan. Median age in years (range) 57.5 (17 to 78). Sex (male/female) 37/14
Index tests pan-fungal PCR assay on 273 specimens
Target condition and reference
standard(s)
revised criteria of the EORTC/MSG
Flow and timing The study was conducted between April 2007 and October 2010. Two hundred seventy-three
consecutive blood samples from 64 risk episodes in 51 patients with haematologic disorders were
analysed
Comparative
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Sugawara 2013 (Continued)
Notes IFD was documented in 14 episodes (21.9%, 9 probable IFDs and 5 possible IFDs). PCR was
positive in all of these 14 episodes, and in 4 of the 50 episodes with no IFD category. In this study,
a considerable number of fungi (44.4%) other than major ones such as Aspergillus and Candida
species were positive by PCR. Non-major fungi identified were Cunninghamella species, Fusarium
species, Scedosporium apiospermum,Rhodotorula species, Rhizopus species, Paecilomyces lilacinus, and
Penicillium sclerotiorum.
In 10 of the 18 PCR-positive episodes, continued PCR screenings disclosed the clearance of the
fungal DNA during antifungal therapy. The study also evaluated the diagnostic performance of
GM, but GM was also part of the reference standard
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Low Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Low Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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Sugawara 2013 (Continued)
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
von Lilienfeld-Toal 2009
Study characteristics Study characteristics
Patient sampling 70 patients with febrile neutropenia (median leukocyte count 420/mm3) after chemotherapy
Patient characteristics and set-
ting
patients treated between September 2001 and February 2002 and between April 2003 and January
2004 on the hematology ward of the University Hospital Bonn, Germany. Median age in years
(IQR) was 60 (49 to 66). Nunber of males (%) was 38 (54)
Index tests Commercial PCR-based kit to detect the DNA of 20 different pathogens (SeptiFast), including
IFD. PCR testing was performed retrospectively
Target condition and reference
standard(s)
IFD according to the standards of the EORTC/MSG
Flow and timing 784 serum samples of 119 febrile neutropenic episodes in 70 patients with hematological malig-
nancies were analysed
Comparative
Notes The only patient with proven IFD (Candida glabrata in one blood culture which also grew Klebsiella
pneumoniae and Enterococcus faecium) yielded a negative result for fungus in the PCR, although the
PCR did detect Enterococcus faecium. All of the patients with probable IFDs had positive results for
Aspergillus in the PCR.
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
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von Lilienfeld-Toal 2009 (Continued)
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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White 2006
Study characteristics Study characteristics
Patient sampling a group of patients at risk of IA
Patient characteristics and set-
ting
A group of 203 patients at risk of IFD were tested by RT-PCR over a 13-month period (Novem-
ber 2003 to December 2004). The majority (176) were hematology patients, with 133 receiving
remission-induction therapy for acute leukaemia (68 patients) or undergoing SCT (65 patients).
The mean age of patients was 48 years
Index tests RT-PCR
Target condition and reference
standard(s)
IA. The EORTC-MSG criteria
Flow and timing Patients at risk of IFD were tested by RT-PCR over a 13-month period (November 2003 to De-
cember 2004)
Comparative
Notes
Methodological quality Methodological
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection DOMAIN 1: Patient
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test All tests DOMAIN 2: Index
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Low Low
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White 2006 (Continued)
DOMAIN 3: Reference Standard DOMAIN 3: Refer
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing DOMAIN 4: Flo
Was there an appropriate inter-
val between index test and ref-
erence standard?
No
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
BAL: broncho-alveolar lavage
EDTA: ethylenediaminetetraacetic acid
EORTC/MSG: European Organisation for Research and Treatment of Cancer/Mycoses Study Group
GM: galactomannan
HRCT: high-resolution computed tomography
IA: invasive aspergillosis
IFD: invasive fungal disease
ITS: Internal transcribed spacer
PCR: polymerase chain reaction
ELISA: enzyme-linked immunosorbent assay
RCLB: red cell lysis buffer
RT-PCR: real time polymerase chain reaction
SCT: stem cell transplant
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adhurti 2011 no 2x2 data provided
Armenian 2009 no 2x2 data provided
Auberger 2011 Retrospective study
Badiee 2008 no 2x2 data provided
Badiee 2009 no 2x2 data provided
Bernal-Martinez 2011 only sensitivity data provided
Blennow 2010 no 2x2 data provided
Bolehovska 2006 Include several materials and at risk patients (not only haematologic)
Bretagne 1998 retrospective selection of patients at risk of IA from a cohort of haematologic patients
Bu Rong 2005 Case control, not consecutive pts
Bucheidt 2001 case control (control group healthy control)
Bucheidt 2004 no 2x2 data provided
Cesaro 2008 no 2x2 data provided
Challier 2004 retrospective selection
Chryssanthou 1999 Candida PCR
Halliday 2005 Methodological, assay procedure
Hasseine 2010 no 2x2 data provided (published only as abstract)
Hebart 2000 no 2x2 data provided
Hummel 2010 no 2x2 data provided; preliminary selection of patients
Johnson 2012 gold standard different from EORTC; 3 cases only
Jones 1998 BAL only
Jordanides 2005 doesn’t distinguish Aspergillus from Candida
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(Continued)
Kalkank 2010 no 2x2 data provided (published only as abstract)
Kami 2001 This study has combined patient samples from both a non-random sampling strategy and from prospective
sampling. The authors suggest a case-control approach. The study does not follow EORTC/MSG criteria
for defining IA
Kawazu 2004 no 2x2 data provided
Klingspor 2006 only sensitivity data provided
Lass-Florl 2001 only sensitivity data provided
Li 2013 case-control
Liu 2005 Chinese
Mandhanija 2010 terms not according EORTC criteria (e.g., suspected cases)
Millon 2011 case control (retrospective selection of patients GM-posiitive from a cohort of haematologic patients)
Morrissey 2013 efficacy end-points, not diagnostic performance
Nakamura 2010 PCR for bacteria and fungi, one positive case
Scotter 2005 retrospective, case control
Skladny 1999 retrospective, case control
Springer 2013 retrospective, case control
Sun 2010 Chinese
Teifoori 2011 No reference standard; no 2x2 tables; not clear if pts were consecutive and when PCR was performed
Yoo 2005 NASBA
Characteristics of studies awaiting classification [ordered by study ID]
Aguado 2015
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
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Aguado 2015 (Continued)
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Amirrajab 2015
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Chanza 2014
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
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Chanza 2014 (Continued)
Comparative
Notes To be assessed
da Silva 2014
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Danylo 2014
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
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Golas 2013
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Heng 2014
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Reinwald 2013
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
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Reinwald 2013 (Continued)
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Reinwald 2014
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
Shah 2015
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
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Shah 2015 (Continued)
Comparative
Notes To be assessed
Theel 2013
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
White 2013
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
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Zarrinfar 2013
Study characteristics Study characteristics
Patient sampling
Patient characteristics and set-
ting
Index tests
Target condition and reference
standard(s)
Flow and timing
Comparative
Notes To be assessed
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 PCR: single positive requirement 17 2297
2 PCR: two positive requirement 8 1479
Test 1. PCR: single positive requirement.
Review: Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people
Test: 1 PCR: single positive requirement
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Badie 2010 13 12 2 55 0.87 [ 0.60, 0.98 ] 0.82 [ 0.71, 0.90 ]
Barnes 2009 7 53 0 64 1.00 [ 0.59, 1.00 ] 0.55 [ 0.45, 0.64 ]
Cuenca-Estrella 2009 9 16 1 57 0.90 [ 0.55, 1.00 ] 0.78 [ 0.67, 0.87 ]
da Silva 2010 15 14 5 159 0.75 [ 0.51, 0.91 ] 0.92 [ 0.87, 0.96 ]
El Mahallawy 2006 21 11 7 52 0.75 [ 0.55, 0.89 ] 0.83 [ 0.71, 0.91 ]
Ferns 2002 2 10 1 4 0.67 [ 0.09, 0.99 ] 0.29 [ 0.08, 0.58 ]
Florent 2006 29 65 4 69 0.88 [ 0.72, 0.97 ] 0.51 [ 0.43, 0.60 ]
Halliday 2006 13 51 0 31 1.00 [ 0.75, 1.00 ] 0.38 [ 0.27, 0.49 ]
Hebart 2000a 13 8 5 66 0.72 [ 0.47, 0.90 ] 0.89 [ 0.80, 0.95 ]
Hummel 2009 4 17 1 48 0.80 [ 0.28, 0.99 ] 0.74 [ 0.61, 0.84 ]
Landlinger 2010 4 65 0 56 1.00 [ 0.40, 1.00 ] 0.46 [ 0.37, 0.56 ]
Ram rez 2009 7 6 3 109 0.70 [ 0.35, 0.93 ] 0.95 [ 0.89, 0.98 ]
Rogers 2013 13 51 2 80 0.87 [ 0.60, 0.98 ] 0.61 [ 0.52, 0.69 ]
Rogers 2013 20 63 10 39 0.67 [ 0.47, 0.83 ] 0.38 [ 0.29, 0.48 ]
Rogers 2013 12 57 3 74 0.80 [ 0.52, 0.96 ] 0.56 [ 0.48, 0.65 ]
Rogers 2013 16 16 14 86 0.53 [ 0.34, 0.72 ] 0.84 [ 0.76, 0.91 ]
Springer 2011 2 16 1 27 0.67 [ 0.09, 0.99 ] 0.63 [ 0.47, 0.77 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Suarez 2008 15 6 0 103 1.00 [ 0.78, 1.00 ] 0.94 [ 0.88, 0.98 ]
Suarez 2008 11 6 4 103 0.73 [ 0.45, 0.92 ] 0.94 [ 0.88, 0.98 ]
Sugawara 2013 6 2 3 53 0.67 [ 0.30, 0.93 ] 0.96 [ 0.87, 1.00 ]
von Lilienfeld-Toal 2009 3 3 0 113 1.00 [ 0.29, 1.00 ] 0.97 [ 0.93, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. PCR: two positive requirement.
Review: Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people
Test: 2 PCR: two positive requirement
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Badie 2010 13 0 2 67 0.87 [ 0.60, 0.98 ] 1.00 [ 0.95, 1.00 ]
Cuenca-Estrella 2009 9 6 1 67 0.90 [ 0.55, 1.00 ] 0.92 [ 0.83, 0.97 ]
Florent 2006 21 17 12 117 0.64 [ 0.45, 0.80 ] 0.87 [ 0.80, 0.92 ]
Halliday 2006 8 7 5 75 0.62 [ 0.32, 0.86 ] 0.91 [ 0.83, 0.96 ]
Rogers 2013 7 0 23 102 0.23 [ 0.10, 0.42 ] 1.00 [ 0.96, 1.00 ]
Rogers 2013 10 25 20 77 0.33 [ 0.17, 0.53 ] 0.75 [ 0.66, 0.83 ]
Rogers 2013 7 18 8 113 0.47 [ 0.21, 0.73 ] 0.86 [ 0.79, 0.92 ]
Rogers 2013 0 9 15 122 0.0 [ 0.0, 0.22 ] 0.93 [ 0.87, 0.97 ]
Springer 2011 2 4 1 39 0.67 [ 0.09, 0.99 ] 0.91 [ 0.78, 0.97 ]
Suarez 2008 12 0 3 109 0.80 [ 0.52, 0.96 ] 1.00 [ 0.97, 1.00 ]
Suarez 2008 7 0 8 109 0.47 [ 0.21, 0.73 ] 1.00 [ 0.97, 1.00 ]
White 2006 12 14 1 175 0.92 [ 0.64, 1.00 ] 0.93 [ 0.88, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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A D D I T I O N A L T A B L E S
Table1. EuropeanOrganisation forResearch andTreatment ofCancer/Mycoses StudyGroupdefinitions of invasive aspergillosis
Original definitions of Ascioglou 2002 Revised definitions of De Pauw 2008
PROVEN IA Specimen obtained by needle aspiration or biopsy from a normally sterile and clinically or radiologically
abnormal site consistent with an infectious disease processAND
EITHER histopathological, cytopathological, or direct microscopic examination of the specimen in which
hyphae are seen accompanied by evidence of associated tissue damage
OR
recovery of Aspergillus species by culture from the specimen obtained by a sterile procedure excluding bron-
choalveolar lavage, cranial sinus cavity, and urine
PROBABLE IA At least 1 host factor criterion PLUS 1 major (or 2
minor) clinical criteria from abnormal site consistent
with infectionPLUS 1 microbiological criterion
At least 1 host factor PLUS 1 clinical feature PLUS 1
microbiological criterion
POSSIBLE IA At least 1 host factor criterion PLUS
EITHER 1 major (or 2 minor) clinical criterion from
abnormal site consistent with infection OR 1 micro-
biological criterion
At least 1 host factor PLUS 1 clinical feature
Host factor criteria will include the temporal relationship between the onset of fungal disease and the receipt of an allogeneic stem cell
transplant.
Clinical features include for example neutropenia, persistent fever, predisposing conditions, prolonged use of corticosteroids; in the
case of lower respiratory tract infection, the presence of one of the following signs on CT: dense well circumscribed lesions(s) with or
without a halo sign or an air crescent sign, cavity.
Microbiological criteria consist of a positive culture including the presence of fungal elements indicating a mould on microscopy or
recovery by culture of Aspergillus species from sputum, bronchoalveolar lavage (BAL) fluid, bronchial brush or sinus aspirate samples;
positive result for Aspergillus detection of galactomannan antigen in specimens of plasma, serum, BAL, cerebrospinal fluid or two or
more blood samples. Major clinical criteria are, for example, new infiltrates on computerized tomography imaging (e.g. halo sign) or
suggestive radiological findings.
Minor clinical criteria are suggestive symptoms and signs.
The exact definitions of the European Organisation for Research and Treatment of Cancer/Mycoses Study Group criteria and their
host factor, microbiological or clinical criteria can be found in Ascioglou 2002 and De Pauw 2008.
Table 2. Technical details of the PCR methods used in the studies analysed in this review
Study Sam-
ple
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Sam-
ple
vol-
ume
DNA extrac-
tion methodsA
PCR
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C
Tar-
get
gene
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quire-
ments
for
posi-
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ods
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(refs)
Cell
wall
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tionB
DNA
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tion
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
Ex PCR Ex PCR
Hebart
2000a
Whole
blood
5 ml Zy-
mo-
lase
and
NaOH
lysis
buffer
Pro-
tein
pre-
cipita-
tion
and
DNA
pre-
cipita-
tion
PCR-
slot
blot
18S - Yes - Yes Yes Single
Posi-
tive
Ein-
sele
1997
Ferns
2002 Whole
blood
2 ml Lyti-
case
QI-
Aamp Nested
PCR
mtDNA
Yes Yes Yes Yes - Posi-
tive
on two
occa-
sions
Bre-
tagne
1998
Tang
1993
Flo-
rent
2006
Serum 200
µl
- QI-
Aamp
PCR-
ELISA mtDNA
- Yes - Yes Yes Two
Con-
secu-
tive
Posi-
tives
Bre-
tagne
1998
Halli-
day
2006
Whole
blood
500
µl
Lyti-
case GenE-
lute
Nested
PCR
18S Yes Yes - Yes Yes Two
con-
secu-
tive
posi-
tives
Skladny
1999
El
Ma-
hallawy
2006
Serum - Lyti-
case
QI-
Aamp
Stan-
dard
PCR
18S - Yes - Yes - Single
posi-
tive
Williamson
2000
White
2006 Whole
blood
2 ml Glass
beads MagNA
Pure
Nested
qPCR
28S Yes Yes Yes Yes Yes Serial
posi-
tives in
single
episode
Loef-
fler
2002;
Williamson
2000
Suarez
2008
Serum 1 ml
or 200
µl
-
MagNA
Pure
qPCR 28S - Yes - Yes - Single
posi-
tive
Chal-
lier
2004
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
Hum-
mel
2009
Blood 5 ml Lyti-
case
Phe-
nol-
chlo-
ro-
form
Nested
PCR
18S - Yes - Yes - Single
posi-
tive
Skladny
1999
Ramírez
2009
Whole
blood
5 ml Lyti-
case
and
glass
beads
QI-
Aamp
qPCR 18S - Yes - Yes - Single
posi-
tive
Loef-
fler
2000
Barnes
2009
Whole
blood
2 ml Glass
beads MagNA
Pure
Nested
qPCR
28S Yes Yes Yes Yes Yes Con-
firmed
posi-
tiveF
White
2006
Cuenca-
Es-
trella
2009
Whole
blood
and
serum
- - QI-
Aamp
qPCR ITS1 - Yes - Yes Yes Two
con-
secu-
tive
posi-
tives
Yoo
2008
von
Lilien-
feld-
Toal
2009
Whole
blood
10 ml Ce-
ramic
beads
Septi-
fast
qPCR 18S - Yes - Yes Yes -
Lehmann
2008
Landlinger
2010
Whole
blood
3 ml Lyti-
case MagNA
Pure
qPCR 28S - Yes - Yes Yes Single
posi-
tive
Baskova
2007;
Watzinger
2004
Badie
2010 Whole
blood
3 to 5
ml
Lyti-
case
QI-
Aamp
qPCR 18S Yes Yes - Yes - Single
posi-
tive
van
Burik
1998;
Kami
2001;
da
Silva
2010
Serum 5 ml
Blood
Lyti-
case
Pro-
tein
pre-
Stan-
dard
PCR
18S - Yes - Yes - Two
con-
secu-
Ribeiro
2006;
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
cipita-
tion
and
DNA
pre-
cipita-
tion
tive
posi-
tives
van
Burik
1998
Springer
2011
G
Whole
blood
3 ml Glass
beads
High
Pure
PCR
Tem-
plate
Prepa-
ration
Kit
(Roche)
qPCR ITS - Yes - Yes - Single
posi-
tiveH
-
Fast-
Prep-
24
MP
(Biomed-
icals)
Whole
blood
5 ml Glass
beads
Stan-
dard
PCR
- - Yes Yes Yes Yes - Sachse
2009
Rogers
2013
G
Whole
blood
3 ml Glass
beads
High
Pure
PCR
Tem-
plate
Prepa-
ration
Kit
(Roche)
Nested
qPCR
28S Yes Yes Yes Yes Yes Single
posi-
tiveI
White
2006
Springer
2011
qPCR ITS1 Yes Yes Single
posi-
tiveI
Sug-
awara
2013
Whole
blood
1 ml Beads
and
lysis
buffer
Phe-
nol-
chlo-
ro-
form
Nested
PCR
and
se-
18S - Yes - Yes - Single
posi-
tive
Naka-
mura
2010
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Table 2. Technical details of the PCR methods used in the studies analysed in this review (Continued)
quenc-
ing
-: not reported; MagNA Pure: an automated DNA isolation system manufactured by Roche; mtDNA: mitochondrial DNA; PCR:
polymerase chain reaction; QIAamp: QIAamp DNA isolation kit manufactured by Qiagen; Ex: extraction; ITS: Internal Trascribed
Spacer; RCLB: red cell lysis buffer.
A DNA isolation protocols may include steps to remove red and white blood cells, fungal cell wall disruption and DNA purification
kits.
B Lyticase/Zymolase enzymatically digest fungal cells walls; ceramic or glass beads cause mechanical disruption of the cell wall.
C PCR methods used vary between standard PCR where products are resolved on agarose gels to detect positive or negative reactions
or quantitative PCR (qPCR) which allows real time monitoring of the reaction. Nested qPCR involves first round standard PCR and
second round qPCR.
D Negative DNA extraction controls feature a sample blank, e.g. blood or sterile solution, that allows detection of any contamination
in the DNA isolation protocol.
E Positive DNA extraction controls are a sample blank that is spiked with fungal or specific bacterial spores to ensure that the DNA
isolation protocol is working optimally.
F The confirmed positive requires that any single positive sample is confirmed with an additional sample from the same patient. Barnes
2009 also used multiple analyses to determine the effectiveness of single versus multiple positives to yield diagnostic accuracy.
G Studies assessed the effectiveness of more than one assay.
H The study analysed the effect of both single and multiple positives.
I The effects of both single and multiple positives were analysed as well as analyses of combined PCR and galactomannan tests.
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE
1 exp Aspergillosis/
2 exp Pulmonary Aspergillosis/
3 exp Aspergillus/
4 (aspergillosis or aspergillus or aspergilloma or “A.fumigatus” or “A. flavus” or “A. clavatus” or “A. terreus” or “A. niger”).ti,ab.
5 or/1-4
6 exp Nucleic Acid Amplification Techniques/
7 pcr.ti,ab.
8 “polymerase chain reaction*”.ti,ab.
9 or/6-8
10 5 and 9
11 exp Animals/ not Humans/
12 10 not 11
key: ti,ab. = title,abstract
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EMBASE
1 Aspergillosis/
2 Lung Aspergillosis/
3 exp Aspergillus/
4 (aspergillosis or aspergillus or aspergilloma or “A.fumigatus” or “A. flavus” or “A. clavatus” or “A. terreus” or “A. niger”).ti,ab.
5 or/1-4
6 nucleic acid amplification/
7 Polymerase Chain Reaction/
8 pcr.ti,ab.
9 “polymerase chain reaction*”.ti,ab.
10 or/6-9
11 5 and 10
12 (exp Animal/ or Nonhuman/ or exp Animal Experiment/) not Human/
13 11 not 12
key: ti,ab =title,abstract
WEB of Science, LILACS, Database of Abstracts of Reviews of Effects, Health Technology Assessment, Scopus
(Aspergillus or Aspergillosis) AND (Polymerase Chain Reaction or Nucleic Acid Amplification) in title, abstracts and keywords
Appendix 2. QUADAS2 Items
DOMAIN PATIENT
SELECTION
INDEX TEST REFERENCE
STANDARD
FLOW AND TIMING
Description Describe methods of pa-
tient selection: Describe
included patients (prior
testing, presentation, in-
tended use of index test
and setting):
Describe the index test
and how it was con-
ducted and interpreted:
Describe the reference
standard and how it
was conducted and in-
terpreted:
Describe any patients
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2 x 2 table (refer to flow
diagram): Describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard:
Signalling questions
(yes/no/unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
Is the reference standard
likely to correctly classify
the target condition?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Was a case-control de-
sign avoided?
If a threshold was used,
was it pre-specified?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Did all patients receive a
reference standard?
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(Continued)
Did the study avoid in-
appropriate exclusions?
Did all patients receive
the same reference stan-
dard?
Were all patients in-
cluded in the analysis?
Risk of bias: high/low/
unclear
Could the selection of
patients have introduced
bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regarding ap-
plicability: high/low/un-
clear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
Item Patient selection. Code this item: Yes. If the characteristics of the spectrum of patients fulfilled the pre-stated requirements
and the method of recruitment was consecutive, or random samples were taken from consecutive series. No. If the sample does not
fit with what was pre-specified as acceptable or if groups with and without the target disorder were recruited separately, particularly
with healthy controls. Unclear. If there is insufficient information available to make a judgment. Independent index and reference
test (incorporation). Yes.If the index test did not form part of the reference standard. No. If the reference standard formally included
the result of the index test. Unclear If it is unclear whether the results of the index test were used in the final diagnosis. .Index test
blind for reference test results and vice versa. Yes. If test results (index or reference standard) were interpreted blind to the results of
the other test, or blinding is dictated by the test order, or meets the pre-stated assumptions. No.If it is clear that one set of test results
was interpreted with knowledge of the other. Unclear. If it is unclear whether blinding took place. Item Reference Standard Yes. All
reference standards used meet the pre-stated criteria. No. One or more reference standards used do not meet the pre-stated criteria.
Unclear. It is unclear exactly what reference standard was used. Were partial verification and differential verification prevented?
Yes. If all patients, or a random selection of patients, who received the index test went on to receive verification of their disease status
using a reference standard, even if the reference standard was not the same for all patients. No. If some of the patients who received the
index test did not receive verification of their true disease state, and the selection of patients to receive the reference standard was not
random. Unclear. If this information is not reported by the study. Item Flow and timing. Yes.If the time between tests was shorter
than that required, at least for an acceptably high proportion of patients. No. If the time between tests was longer than that required
for an unacceptably high proportion of patients. Unclear. If information on timing of tests is not provided.
WH A T ’ S N E W
Date Event Description
14 September 2015 Amended Errors in text corrected
14 September 2015 New citation required but conclusions have not
changed
Errors in text corrected
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We intended to use QUADAS, as described in the protocol, but switched to QUADAS-2 for the review.
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